Innovating Precision Neuropsychiatry & Propelling Next Generation Drug R&D

Thank you to our speakers, sponsors, and delegates who joined us in September for the summit! If you are interested in the 2025 event, please register your interest below to receive updates on the meeting!

With Karuna’s schizophrenia program coined as the most anticipated drug launch of 2024, and 2023 bringing brand new regulatory guidance, surging investment has reinvigorated the space with new targets, mechanisms, and technologies to transform the mental health treatment landscape.

Capitalizing on a new wave of pipeline momentum, the 7th Neuropsychiatric Drug Development Summit returned as the industry’s premier gathering, showcasing the latest circuit-based target innovation, EEG and digital biomarker data, in vivo and in vitro model advances, pioneering precision psychiatry approaches and more.

Attendees joined discovery, preclinical, translational, clinical, regulatory, and commercial experts from Karuna, Janssen, AbbVie, Otsuka, Alto Neuroscience, Lykos, Lundbeck, Compass, Biogen, DelixTherapeutics, Boehringer Ingelheim, and more as they addressed biopharma’s most pressing challenges in a collaborative atmosphere to accelerate the race to approval for transformative neuropsychiatric candidates.

Our 2024 Expert Speaker Faculty Included:

Berra Yazar Klosinski, Neuropsychiatric Drug Development

Berra Yazar-Klosinski

Chief Scientific Officer

Lykos Therapeutics

Cornelia Dorner-Ciossek, Neuropsychiatric Drug Development

Cornelia Dorner-Ciossek

Head of Digital Health TA CNS Retinopathies Emerging Areas

Boehringer Ingelheim

Daniel Karlin, Neuropsychiatric Drug Development

Daniel Karlin

Chief Medical Officer

MindMed

Matt Harlin, Neuropsychiatric Drug Development

Matthew Harlin

Senior Director - Discovery Research & Early Phase , Translational Medicine

Otsuka

Patricio O'Donnell, Neuropsychiatric Drug Development

Patricio O’Donnell

Vice President - Translational Medicine

Alto Neuroscience

Snezana Milanovic, Neuropsychiatric Drug Development

Snezana Milanovic

Senior Director, TMED & Early Development

Sumitomo Pharma America, Inc.

Steve Brannan, Neuropsychiatric Drug Development

Stephen Brannan

Former Chief Medical Officer

Karuna Therapeutics

Wayne Drevets, Neuropsychiatric Drug Development

Wayne Drevets

Vice President, Disease Area Team Leader, Neuroscience

Johnson & Johnson Services, Inc

Access the Comprehensive Event Guide With 35+ Speakers, 2 Tracks of Content, 4 Pre-conference Workshops & More!

Neuropsychiatric Drug Development

Previous Attending Companies Include:

Neuropsychiatry Summit Attending Companies (1)
Picture of Aaron Koenig, Neuropsychiatric Drug Development

“An engaging and interactive conference, providing an opportunity for R&D leaders in neuropsychiatry to roll up their sleeves and discuss issues that we are collectively facing in this rapidly evolving field.” 

Aaron Koenig, Chief Medical Officer, Delix Therapeutics

Snezana Milanovic, Neuropsychiatric Drug Development

“The upcoming years look promising for the field of psychiatry. According to J.P. Morgan’s Annual Biopharma Licensing and Venture Report, 2023 witnessed significant venture capital investment in neuroscience, a trend that is expected to persist. Accompanying this surge is a notable increase in investments in mental health apps and AI-driven mental health solutions. I am eager to learn how drug developers plan to capitalize on this favorable landscape.” 

Snezana Milanovic, Senior Director, TMED & Early Development, Sumitomo Pharma America

Our 2024 Partners Included:

Other Events in the World CNS Series: